Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant IL2RA (Basiliximab Biosimilar) antibody

Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, WB, BR, IF, IHC Host: Rabbit Chimeric unconjugated Recombinant Antibody
Catalog No. ABIN5668051
  • Target See all IL2RA (Basiliximab Biosimilar) products
    IL2RA (Basiliximab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human, Cynomolgus, Rhesus Monkey
    Host
    • 2
    • 1
    Rabbit
    Clonality
    • 3
    Chimeric
    Conjugate
    • 3
    This IL2RA (Basiliximab Biosimilar) antibody is un-conjugated
    Application
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    Flow Cytometry (FACS), Western Blotting (WB), Blocking Reagent (BR), Immunofluorescence (IF), Immunohistochemistry (IHC)
    Specificity
    Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
    Cross-Reactivity
    Cynomolgus, Rhesus Monkey
    Characteristics

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Purified antibody.
    Purity
    > 98 % as determined by SDS-PAGE
    Endotoxin Level
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogen
    Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
    Isotype
    IgG kappa
  • Application Notes
    Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
    Comment

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions
    For Research Use only
  • Buffer
    PBS with 0.02 % Proclin 300.
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    IL2RA (Basiliximab Biosimilar)
    Abstract
    IL2RA (Basiliximab Biosimilar) Products
    Synonyms
    CD25 antibody, IDDM10 antibody, IL2R antibody, TCGFR antibody, IL2RAC antibody, Il2r antibody, Ly-43 antibody, interleukin 2 receptor subunit alpha antibody, interleukin 2 receptor, alpha chain antibody, IL2RA antibody, Il2ra antibody
    Background
    Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.
    UniProt
    P01589
You are here:
Support